{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:08:08Z","timestamp":1790219288091,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["19182MFDS406"],"award-info":[{"award-number":["19182MFDS406"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government-wide R"},{"name":"Ajou University School of Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hydroxychloroquine has recently received attention as a treatment for COVID-19. However, it may prolong the QTc interval. Furthermore, when hydroxychloroquine is administered concomitantly with other drugs, it can exacerbate the risk of QT prolongation. Nevertheless, the risk of QT prolongation due to drug-drug interactions (DDIs) between hydroxychloroquine and concomitant medications has not yet been identified. To evaluate the risk of QT prolongation due to DDIs between hydroxychloroquine and 118 concurrent drugs frequently used in real-world practice, we analyzed the electrocardiogram results obtained for 447,632 patients and their relevant electronic health records in a tertiary teaching hospital in Korea from 1996 to 2018. We repeated the case\u2013control analysis for each drug. In each analysis, we performed multiple logistic regression and calculated the odds ratio (OR) for each target drug, hydroxychloroquine, and the interaction terms between those two drugs. The DDIs were observed in 12 drugs (trimebutine, tacrolimus, tramadol, rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, piperacillin\/tazobactam, isoniazid, clarithromycin, and furosemide), all with a\n                    <jats:italic>p<\/jats:italic>\n                    value of\u2009&lt;\u20090.05 (OR 1.70\u201317.85). In conclusion, we found 12 drugs that showed DDIs with hydroxychloroquine in the direction of increasing QT prolongation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-86321-z","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T07:06:58Z","timestamp":1616656018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice"],"prefix":"10.1038","volume":"11","author":[{"given":"Byung Jin","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeryung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wou Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dukyong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"86321_CR1","unstructured":"Administration USFaD. Who coronavirus disease (covid-19) dashboard. 2020."},{"key":"86321_CR2","doi-asserted-by":"publisher","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"20","author":"P Colson","year":"2020","unstructured":"Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P. & Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight covid-19. Int. J. Antimicrob. Agents 20, 105932 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"86321_CR3","first-page":"20","volume":"20","author":"J Gao","year":"2020","unstructured":"Gao, J., Tian, Z. & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies. Biosci. Trends 20, 20 (2020).","journal-title":"Biosci. Trends"},{"key":"86321_CR4","doi-asserted-by":"publisher","first-page":"106057","DOI":"10.1016\/j.ijantimicag.2020.106057","volume":"20","author":"K Mubagwa","year":"2020","unstructured":"Mubagwa, K. Cardiac effects and toxicity of chloroquine: A short update. Int. J. Antimicrob. Agents 20, 106057\u2013106057 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"86321_CR5","first-page":"20","volume":"20","author":"DM Roden","year":"2020","unstructured":"Roden, D. M., Harrington, R. A., Poppas, A. & Russo, A. M. Considerations for drug interactions on QTC in exploratory covid-19 (coronavirus disease 2019) treatment. Circulation 20, 20 (2020).","journal-title":"Circulation"},{"key":"86321_CR6","doi-asserted-by":"publisher","first-page":"30085","DOI":"10.1016\/j.medmal.2020.03.006","volume":"50","author":"JM Molina","year":"2020","unstructured":"Molina, J. M. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe covid-19 infection. Med. Mal. Infect. 50, 30085\u201330088 (2020).","journal-title":"Med. Mal. Infect."},{"key":"86321_CR7","first-page":"20","volume":"20","author":"E Chorin","year":"2020","unstructured":"Chorin, E. et al. QT interval prolongation and torsade de pointes in patients with covid-19 treated with hydroxychloroquine\/azithromycin. Heart Rhythm 20, 20 (2020).","journal-title":"Heart Rhythm"},{"key":"86321_CR8","first-page":"20","volume":"20","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro, N. J. et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (covid-19). JAMA Cardiol. 20, 20 (2020).","journal-title":"JAMA Cardiol."},{"key":"86321_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492\u2013509 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"86321_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"86321_CR11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","volume":"77","author":"BA Pons-Estel","year":"2018","unstructured":"Pons-Estel, B. A. et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549\u20131557 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"86321_CR12","doi-asserted-by":"publisher","first-page":"e0176222","DOI":"10.1371\/journal.pone.0176222","volume":"12","author":"Y-G Kim","year":"2017","unstructured":"Kim, Y.-G. et al. Ecg-view ii, a freely accessible electrocardiogram database. PLoS\u00a0One 12, e0176222 (2017).","journal-title":"PLoS\u00a0One"},{"key":"86321_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4258\/hir.2018.24.3.242","volume":"24","author":"D Chung","year":"2018","unstructured":"Chung, D. et al. Construction of an electrocardiogram database including 12 lead waveforms. Healthc. Inform. Res. 24, 242\u2013246 (2018).","journal-title":"Healthc. Inform. Res."},{"key":"86321_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","volume":"31","author":"J Ducharme","year":"1996","unstructured":"Ducharme, J. & Farinotti, R. Clinical pharmacokinetics and metabolism of chloroquine. Clin. Pharmacokinet. 31, 257\u2013274 (1996).","journal-title":"Clin. Pharmacokinet."},{"key":"86321_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.ijcard.2007.04.055","volume":"127","author":"P Stas","year":"2008","unstructured":"Stas, P., Faes, D. & Noyens, P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int. J. Cardiol. 127, e80\u2013e82 (2008).","journal-title":"Int. J. Cardiol."},{"key":"86321_CR16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1086\/516138","volume":"25","author":"DL Paterson","year":"1997","unstructured":"Paterson, D. L. & Singh, N. Interactions between tacrolimus and antimicrobial agents. Clin. Infect. Dis. 25, 1430\u20131440 (1997).","journal-title":"Clin. Infect. Dis."},{"key":"86321_CR17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/0006-2952(90)90571-2","volume":"40","author":"JO Nwankwo","year":"1990","unstructured":"Nwankwo, J. O., Garba, M. A., Chinje, C. E., Mgbojikwe, L. O. & Emerole, G. O. Possible chloroquine-induced modification of n-acetylation of isoniazid and sulphadimidine in the rat. Biochem. Pharmacol. 40, 654\u2013659 (1990).","journal-title":"Biochem. Pharmacol."},{"key":"86321_CR18","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1128\/AAC.02794-13","volume":"58","author":"S Pukrittayakamee","year":"2014","unstructured":"Pukrittayakamee, S. et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob. Agents Chemother. 58, 3354\u20133359 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"86321_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bcp.12160","volume":"76","author":"AK Miller","year":"2013","unstructured":"Miller, A. K. et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br. J. Clin. Pharmacol. 76, 858\u2013867 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"86321_CR20","volume-title":"Macrolide Antibiotics: Chemistry, Biology, and Practice","author":"S Omura","year":"2002","unstructured":"Omura, S. Macrolide Antibiotics: Chemistry, Biology, and Practice (Elsevier, 2002)."},{"key":"86321_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/00003495-199957050-00017","volume":"57","author":"CM Perry","year":"1999","unstructured":"Perry, C. M. & Markham, A. Piperacillin\/tazobactam. Drugs 57, 805\u2013843 (1999).","journal-title":"Drugs"},{"key":"86321_CR22","doi-asserted-by":"crossref","unstructured":"Saunders, M. J., & Evans, C. A. Covid-19, tuberculosis, and poverty: Preventing a perfect storm. 2020.","DOI":"10.1183\/13993003.01348-2020"},{"key":"86321_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000492616","volume":"27","author":"M Behzadi","year":"2018","unstructured":"Behzadi, M., Joukar, S. & Beik, A. Opioids and cardiac arrhythmia: A literature review. Med. Princ. Pract. 27, 401\u2013414 (2018).","journal-title":"Med. Princ. Pract."},{"key":"86321_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ajad.13031","volume":"29","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Challenges to opioid use disorders during covid-19. Am. J. Addict. 29, 174 (2020).","journal-title":"Am. J. Addict."},{"key":"86321_CR25","doi-asserted-by":"crossref","unstructured":"Alexander, G. C., Stoller, K. B., Haffajee, R. L., & Saloner, B. An epidemic in the midst of a pandemic: Opioid use disorder and covid-19. 2020.","DOI":"10.7326\/M20-1141"},{"key":"86321_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1208\/s12248-008-9037-4","volume":"10","author":"M Sinz","year":"2008","unstructured":"Sinz, M., Wallace, G. & Sahi, J. Current industrial practices in assessing cyp450 enzyme induction: Preclinical and clinical. AAPS J. 10, 391\u2013400 (2008).","journal-title":"AAPS J."},{"key":"86321_CR27","first-page":"1031","volume":"28","author":"BS Mayhew","year":"2000","unstructured":"Mayhew, B. S., Jones, D. R. & Hall, S. D. An in vitro model for predicting in vivo inhibition of cytochrome p450 3a4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28, 1031\u20131037 (2000).","journal-title":"Drug Metab. Dispos."},{"key":"86321_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40262-015-0268-0","volume":"54","author":"D Lassen","year":"2015","unstructured":"Lassen, D., Damkier, P. & Br\u00f8sen, K. The pharmacogenetics of tramadol. Clin. Pharmacokinet. 54, 825\u2013836 (2015).","journal-title":"Clin. Pharmacokinet."},{"key":"86321_CR29","first-page":"20","volume":"20","author":"JR Giudicessi","year":"2020","unstructured":"Giudicessi, J. R., Noseworthy, P. A., Friedman, P. A. & Ackerman, M. J. Urgent guidance for navigating and circumventing the QTC-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (covid-19). Mayo Clin. Proc. 20, 20 (2020).","journal-title":"Mayo Clin. Proc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86321-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:47:32Z","timestamp":1670028452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86321-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86321"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86321-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"13 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6918"}}